| Identification | Back Directory | [Name]
Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- | [CAS]
2417955-18-9 | [Synonyms]
Benzaldehyde, 2-hydroxy-6-[[(3S)-4-[[2-(2-hydroxyethyl)-3-pyridinyl]carbonyl]-3-morpholinyl]methoxy]- | [Molecular Formula]
C20H22N2O6 | [MOL File]
2417955-18-9.mol | [Molecular Weight]
386.4 |
| Chemical Properties | Back Directory | [Boiling point ]
637.5±55.0 °C(Predicted) | [density ]
1.338±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
7.79±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
Osivelotor is an allosteric modulator of haemoglobin S. | [Uses]
Osivelotor is an orally effective small molecule. Osivelotor is an allosteric regulator of deoxyhemoglobin S (HbS). Osivelotor increases the affinity of HbS to oxygen, inhibits HbS polymerization, and thus prevents erythrocyte sickling in the blood. Osivelotor can be used for research of sickle cell disease (SCD) [1] [2]. | [in vivo]
Osivelotor (20-150 mg/kg; Oral gavage; Once a day; 21 days) significantly improves red blood cell health, reduces red blood cell sickle response and maintains oxygen delivery to peripheral tissues in a mouse model of sickle cell disease [2]. | Animal Model: | Male knock-in Townes mice with an HbSS genotype [2] | | Dosage: | 20, 40, 75 and 150mg/kg | | Administration: | Oral gavage (i.g.); once a day; 21 days | | Result: | Reduced red blood cell sickling, improved red blood cell deformability and prolonged red blood cell half-life.
Restored haemoglobin levels to the normal range.
Improved oxygen delivery and increased tolerance to severe hypoxia. |
| [References]
[1] WHO Drug Information-World Health Organization (WHO).
[2] Dufu K, et al. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183. DOI:10.1111/bjh.18771 |
|
|